The Trojan Investment Funds all have an absolute return objective and any comparisons against indices are for illustrative purposes only. The Trojan Capital Fund is an equity fund that aims to provide substantial capital growth over the longer term.
Another very difficult month for equity markets. At 22% before rallying to -11.9% at the month end. Against this background the Fund held up fairly well and produced a total return of -6.2%. We took advantage of market weakness to increase the Fund's equity holdings and cash levels fell from 19% to 14% during the month.New holdings were purchased in BAT Industries, Centrica and Johnson & Johnson, the resilient US healthcare company. Aveva, Muhlbauer and Vacon were all sold while we added to a number of existing holdings such as BG, Bic, GlaxoSmithKline, Royal Dutch Shell and Tesco.
Latest Price | 520.40p | IMA Sector | Global |
---|---|---|---|
Currency | British Pound | Launch Date | 06/03/2006 |
Fund Size | n/a | Fund Manager | Ruth Keattch |
ISIN | GB00B0ZJ0230 | Dividend | 1.57p |
Date | 21-Nov-2024 |
---|---|
NAV | 520.40p |
Currency | GBP |
Change | -0.15p |
% | -0.03% |
YTD change | 64.91p |
YTD % | 14.25% |
Fund Inception | 06/03/2006 |
---|---|
Fund Manager | Ruth Keattch |
TER | 1.12 (31-Jan-2014) |
Minimum Investment | |
---|---|
Initial | £10000 |
Additional | £100,000 |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.00% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.25 |
You are here: research